Group 1 - The core viewpoint of the article is that the company is optimistic about the potential growth of its investment in Tai Zhou Xing Pu Tai Biopharmaceutical Co., Ltd. due to the upcoming large-scale market entry of domestic oral semaglutide this year [2] - The company currently holds a 3.33% stake in Tai Zhou Xing Pu Tai Biopharmaceutical Co., Ltd., indicating a strategic investment aimed at enhancing its position within the industry supply chain [2]